Zafgen Inc. (Nasdaq: ZFGN) reported positive results from a Phase 3 trial of beloranib in patients with Prader-Willi syndrome sending the stock price soaring $3.40 to $9.02.
Zafgen reports upbeat trial results
January 20, 2016 at 12:00 PM EST
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.